Display Settings:

Format

Send to:

Choose Destination
Br J Cancer. 2007 Feb 12;96(3):417-23. Epub 2007 Jan 9.

EpCAM (CD326) finding its role in cancer.

Author information

  • 1Micromet, Inc., 2110 Rutherford Road, Carlsbad, CA, 92008, USA. Patrick.baeuerle@micromet-inc.com

Erratum in

  • Br J Cancer. 2007 May 7;96(9):1491.

Abstract

Although epithelial cell adhesion/activating molecule (EpCAM/CD326) is one of the first tumour-associated antigens identified, it has never received the same level of attention as other target proteins for therapy of cancer. It is also striking that ever since its discovery in the late 1970s the actual contribution of EpCAM to carcinogenesis remained unexplored until very recently. With a First International Symposium on EpCAM Biology and Clinical Application this is now changing. Key topics discussed at the meeting were the frequency and level of EpCAM expression on various cancers and its prognostic potential, the role of EpCAM as an oncogenic signalling molecule for cancer cells, recent progress on EpCAM-directed immunotherapeutic approaches in clinical development and the interaction of EpCAM with other proteins, which may provide a basis for a therapeutic window and repression of its growth-promoting signalling in carcinoma. Future research on EpCAM may benefit from a unified nomenclature and more frequent exchange among those who have been working on this cancer target during the past 30 years and will do so in the future.

PMID:
17211480
[PubMed - indexed for MEDLINE]
PMCID:
PMC2360029
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk